Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study

Clinical Trial Title

A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.

Clinical Trial Protocol Description:

Response directed therapy in high risk pediatric Hodgkin lymphoma with brentuximab added to standard therapy.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 2 and 22 years of age at the time of enrollment.
  • Have newly  diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages:
    • Stage IIB with bulk
    • Stage IIIB
    • Stage IVA
    • Stage IVB

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Nitin Sane

(312) 355-0741